TITLE

Natalizumab and PML: a risky business?

AUTHOR(S)
Clifford, David B.
PUB. DATE
October 2008
SOURCE
Gut;Oct2008, Vol. 57 Issue 10, p1347
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the development of treatments including natalizumab (Tysabri), a drug used to treat Crohn's disease. It cites that the drug is a humanized monoclonal antibody against 4-integrin, which is first approved for treatment on relapsing multiple sclerosis (MS). It contends that this drug minimizes the activity of MS as shown by the development of magnetic resonance (MR) brain lesions and slowing progression of disability.
ACCESSION #
34640810

 

Related Articles

  • Sarcoidosis complicating treatment with natalizumab for Crohn's disease. Parisinos, C. A.; Lees, C. W.; Wallace, W. A. H.; Satsangi, J. // Thorax;Dec2011, Vol. 66 Issue 12, p1109 

    Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had...

  • Progressive Multifocal Leukoencephalopathy and Newer Biological Agents. Berger, J. R. // Drug Safety;2010, Vol. 33 Issue 11, p969 

    Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the brain due to a polyoma virus, JC virus. Despite the ubiquity of this virus, PML is rare and almost always seen in association with an underlying immunosuppressive condition. In the last 30 years, AIDS has...

  • Natalizumab for moderateto- severe Crohn disease.  // WHO Drug Information;2008, Vol. 22 Issue 1, p20 

    The article reports on the approval of natalizumab antibodies in treating multiple sclerosis and moderate-to-severe Crohn disease by the Food and Drug Administration (FDA) in the U.S. FDA proves that natalizumab is an effective agent in treating Crohn disease in patients with evidence of...

  • Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Kumar, Neeraj; Rodriguez, Moses // Multiple Sclerosis (13524585);Feb2004, Vol. 10 Issue 1, p85 

    Background: Animal studies have shown that some human monoclonal antibodies promote myelin repair in models of demyelinating disease. Scleromyxedema is a dermatologic disorder associated with a monoclonal gammopathy and neurologic manifestations. The reason for occurrence of cutaneous reactions...

  • Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis. Trebst, Corinna; Vo�, Elke; Skripuletz, Thomas; Stangel, Martin // Current Medicinal Chemistry;Mar2010, Vol. 17 Issue 7, Special section p640 

    Multiple sclerosis (MS) is considered to be an autoimmune disease leading to inflammatory demyelination and axonal damage in the central nervous system (CNS). Current treatments involve non-specific immunosuppression and immunomodulation. The development of monoclonal antibodies for therapeutic...

  • Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease./GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous...  // Current Medical Literature: Multiple Sclerosis;2013, Vol. 5 Issue 1, p18 

    Reviews of the articles "Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease," by H. Perron and colleagues and "GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated...

  • Case history: Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Steinman, Lawrence // Nature Reviews Drug Discovery;Jun2005, Vol. 4 Issue 6, p510 

    Immunologists have long hypothesized that particular 'molecular addresses' govern lymphocyte entry to a given organ. In 1992,α4β1 integrin was identified as the key molecule involved in homing to inflamed regions of the brain. An antibody toα4β1integrin blocked paralysis in an animal...

  • Multiple Sclerosis: Current and Future Treatment Options. Rizvi, S. // Endocrine, Metabolic & Immune Disorders - Drug Targets;Dec2007, Vol. 7 Issue 4, p292 

    Multiple Sclerosis is an inflammatory and degenerative disorder involving the central nervous system. It primarily affects young adults and may result in significant long-term disability. The most common initial presentation is relapsing remitting, followed by a chronic progressive course. In a...

  • The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. Kremer, David; Förster, Moritz; Schichel, Tanja; Göttle, Peter; Hartung, Hans-Peter; Perron, Hervé; Küry, Patrick // Multiple Sclerosis Journal;Aug2015, Vol. 21 Issue 9, p1200 

    Background: The envelope protein (ENV) of the human endogenous retrovirus type W is implicated in inflammatory reactions in multiple sclerosis (MS) but also interferes with oligodendroglial maturation. A neutralizing antibody GNbAC1 has been developed and successfully been tested in clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics